October 28, 2021

Pfizer: Vaccine booster restores full protection against Covid-19.

Pfizer and BioNTech reported on October 22 that its coronavirus disease 2019 (Covid-19) vaccine booster showed complete protection against the disease in a large-scale trial.

A Pfizer-BioNTech booster dose was given to over 10,000 people aged 16 and above who had previously received the Pfizer-BioNTech initial two-dose series in Phase 3 randomized, controlled experiment.

When compared to individuals who did not receive a booster, it exhibited 95.6 percent relative vaccination efficacy.

These are the first efficacy findings from a randomized, double-blind, placebo-controlled Covid-19 booster experiment.

Pfizer Chairman and Chief Executive Officer Albert Bourla remarked, “These results provide further proof of the benefits of boosters as we try to keep individuals well-protected against this disease.”

The US Food and Drug Administration approved booster shots for the Pfizer-BioNTech Covid-19 vaccine last month, allowing a single booster dose to be given at least 6 months after the primary series to people aged 65 and up, as well as those aged 18 to 64 who have had frequent institutional or occupational exposure to SARS-CoV-2.

Please follow and like us:
Tweet 2k
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments

Enjoy this blog? Please spread the word :)

Would love your thoughts, please comment.x